



RECEIVED  
CENTRAL FAX CENTER

AUG 04 2004

OFFICIAL

## Facsimile Cover

This facsimile contains information that (a) is or may be LEGALLY PRIVILEGED, PROPRIETARY IN NATURE, OR OTHERWISE PROTECTED BY LAW FROM DISCLOSURE and (b) is intended for the use of the Addressee(s) named herein. If you are not the intended recipient, an addressee, or the person responsible for delivering this to an addressee, you are hereby notified that reading, copying or distributing this facsimile is prohibited. If you have received this facsimile in error, please telephone us immediately and mail the facsimile back to us at the address to the right. Thank you.

Bryan Cave LLP  
1290 Avenue of the Americas  
New York, NY 10104-3300  
Tel (212) 541-2000  
Fax (212) 541-4630  
www.bryancave.com

Date: August 4, 2004  
From: Stephen J. Brown, Reg. No. 43,519

Telephone: (212) 541-1242

To: Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Fax Number: (703) 872-9307  
Telephone: (571) 272-0581

Attention: Examiner Brian S. Kwon  
Art Unit: 1614

Matter: 0111697  
Message:

Number of Pages Including Cover: 13

In Re: U.S. Patent Application Serial No. 09/738,610

Filed: December 15, 2000

For: L-ASCORBIC ACID AND PECTIN COMPOSITION

Ref: 20529 US C038435/0111697

### TO SENDER:

Do you wish to have your copy returned?

☒ Yes ☐ No

Do you wish to be contacted when Fax is Sent?

☐ Yes ☒ No

Do you wish to have the TRANSMISSION REPORT sent to you?

☒ Yes ☐ No

Do you wish to be contacted at your home/office if fax CANNOT be sent within one hour?

☐ Yes ☒ No

Phone No:

If all pages are not received, please call (212) 541-2136 or (212) 541-1294

Docket No.: 20529 US (C038435/0111697)

REPLY UNDER  
37 CFR § 1.116  
-----  
EXPEDITED PROCEDURE  
-----  
TECHNOLOGY CENTER 1600

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

AUG 04 2004

In re Application of: )  
Chyi-Cheng CHEN *et al.* ) Examiner: B. Kwon  
Serial No.: 09/738,610 ) Art Unit: 1614  
Filed: December 15, 2000 )  
For: L-ASCORBIC ACID AND PECTIN )  
COMPOSITION )

OFFICIAL

New York, New York  
August 4, 2004SUPPLEMENTAL RESPONSE INCLUDING AMENDMENT

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the Advisory Action mailed July 26, 2004 denying entry of the amendments presented in the Response To Office Action mailed on June 7, 2004, and telephonic Examiner's Interviews conducted on July 8 and 9, 2004. Should there be a fee required in connection with this Supplemental Response, please charge any such fees to Deposit Account No. 02-4467. A duplicate copy of this sheet is enclosed.

Docket No.: 20529 US (C038435/0111697)

REPLY UNDER  
37 CFR § 1.116

EXPEDITED PROCEDURE

TECHNOLOGY CENTER 1600

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
Chyi-Cheng CHEN *et al.* ) Examiner: B. Kwon  
Serial No.: 09/738,610 ) Art Unit: 1614  
Filed: December 15, 2000 )  
For: L-ASCORBIC ACID AND PECTIN )  
COMPOSITION )

New York, New York  
August 4, 2004SUPPLEMENTAL RESPONSE INCLUDING AMENDMENTMail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the Advisory Action mailed July 26, 2004 denying entry of the amendments presented in the Response To Office Action mailed on June 7, 2004, and telephonic Examiner's Interviews conducted on July 8 and 9, 2004. Should there be a fee required in connection with this Supplemental Response, please charge any such fees to Deposit Account No. 02-4467. A duplicate copy of this sheet is enclosed.

Application No.: 09/738,610  
Amendment Dated: August 4, 2004  
Reply to Advisory Action Dated: July 26, 2004

Because the Office Action mailed March 5, 2004 (Paper No. 02142004) made the rejection of the pending claims final, consideration of this response pursuant to the expedited procedure for response after final rejection set forth in MPEP § 714.13 (8<sup>th</sup> Ed., Rev. 2, May 2004, pp. 700-227 to 700-228) respectfully is solicited.

Please amend the application as follows:

**AMENDMENTS TO THE CLAIMS** are reflected in the listing of claims, which begins on page 3 of this paper.

**REMARKS** begin on page 9 of this paper.